Kardiologie up2date 2016; 12(03): 220-223
DOI: 10.1055/s-0042-114864
Hotline – Koronare Herzerkrankung und Atherosklerose
© Georg Thieme Verlag KG Stuttgart · New York

SGLT2-Hemmung und Reduktion kardiovaskulärer Ereignisse bei Diabetes

Katharina Schütt
Nikolaus Marx
Further Information

Publication History

Publication Date:
29 September 2016 (online)


SGLT2-inhibitors are a novel class of antidiabetic drugs that increase urinary glucose excretion thus lowering blood glucose levels. In addition to their glucose-lowering properties, these agents reduce weight and blood pressure and seem to exhibit additional beneficial effect in the cardiovascular system. The recently published EMPA-REG OUTCOME study demonstrated a reduction in cardiovascular mortality, overall mortality as well as hospitalisation for heart failure by the SGLT2-inhibitor empagliflozin in a population of patients with type 2 diabetes and high cardiovascular risk.